News Brief: Pfizer Q3 2024 Earnings Report
Summary
Pfizer reported better-than-expected Q3 earnings and revenue, despite a sales decline. The company raised its full-year profit guidance, citing cost-cutting measures and solid performance. This follows a recent deal with the Trump administration on drug pricing.
Key Points
- Earnings & Revenue: Adjusted EPS of $0.87 vs. $0.63 expected; Revenue of $16.65B vs. $16.58B expected, though down 6% year-over-year.
- 2024 Guidance: Raised adjusted EPS forecast to $3.00-$3.15 from $2.90-$3.10; maintained revenue guidance of $61B-$64B.
- Cost-Cutting: Plans to reduce costs by $4.5B by end of 2025 and $7.7B by end of 2027.
- COVID Product Sales: Declined due to lower demand for Comirnaty (vaccine) and Paxlovid (antiviral pill).
- Non-COVID Products: Strong performance from Eliquis, Vyndaqel, and Nurtec.
- Deal with Trump Administration: Pfizer agreed to a three-year grace period from pharmaceutical-specific tariffs in exchange for investing $70B in U.S. manufacturing.
- Acquisition & Legal Battle: In a bidding war with Novo Nordisk for obesity biotech Metsera; Pfizer alleges anticompetitive behavior.
新闻简报：辉瑞2024年第三季度财报
总结
辉瑞第三季度盈利和收入超出预期，尽管销售额有所下降。公司提高了全年利润指引， citing 成本削减措施和稳健业绩。此前，辉瑞与特朗普政府达成了药品定价协议。
关键点
- 盈利与收入：调整后每股收益0.87美元，预期0.63美元；收入166.5亿美元，预期165.8亿美元，但同比下降6%。
- 2024年指引：将调整后每股收益预测从2.90-3.10美元上调至3.00-3.15美元；维持610-640亿美元的收入指引。
- 成本削减：计划到2025年底削减45亿美元成本，到2027年底削减77亿美元。
- 新冠产品销售额：因Comirnaty（疫苗）和Paxlovid（抗病毒药）需求下降而下滑。
- 非新冠产品：Eliquis、Vyndaqel和Nurtec表现强劲。
- 与特朗普政府的协议：辉瑞同意投资700亿美元于美国制造业，以换取三年免受药品特定关税的宽限期。
- 收购与法律纠纷：与诺和诺德竞购肥胖症生物技术公司Metsera；辉瑞指控其存在反竞争行为。
Original Article Link: https://www.cnbc.com/2025/11/04/pfizer-pfe-earnings-q3-2025.html